1. The potential neuroprotective actions of the A 3 adenosine receptor (A 3 AR) were investigated using mice with functional deletions of the A 3 AR (A 3 AR −/− ) in behavioral assessments of analgesia, locomotion, tests predictive of depression and anxiety, and the effects of mild hypoxia on cognition and neuronal survival.
INTRODUCTION
The four subtypes of adenosine receptors (ARs), A 1 , A 2A , A 2B , and A 3 , are widely distributed throughout the body (Fredholm et al., 2001) . Activation of the G proteincoupled receptors A 1 and A 3 inhibits adenylate cyclase activity, while activation of the A 2A and A 2B subtypes stimulates this enzyme. Stimulation of A 1 , A 2B , and A 3 subtypes also activate phospholipases (Feoktistov et al., 2002; Parsons et al., 2000) . In the periphery, A 3 AR activation by either endogenous adenosine or exogenously administered agonists appears to be cardioprotective (Parsons et al., 2000) , an effect mediated in cultured myocytes by phospholipase D. However, this cell-protective function of A 3 AR may not be universally observed. The cardioprotective, hemodynamic, and toxic effects of A 3 AR agonists appears to be species-dependent (Lasley et al., 1999) . In rodents, acute activation of A 3 ARs increases the release of proinflammatory agents such as histamine and TNFα (Ramkumar et al., 1993; Sajjadi et al., 1996; Salvatore et al., 2000; van Schaick et al., 1996) . Moreover, deletion of the A 3 AR in mice enhanced adenosine-stimulated coronary blood flow (Talukder et al., 2002) and generally improved cardiac tolerance to ischemia (Guo et al., 2001; Harrison et al., 2002) . These results suggest that, in some species, inhibition of A 3 AR activity may protect tissues, possibly by suppressing proinflammatory processes.
The functions of the A 3 AR in the central nervous system (CNS) appear to be equally complex. The precise density and localization of A 3 AR in the brain remains unclear, due in part to the absence of selective, high affinity ligands or nucleotide probes (Rivkees et al., 2000) . Nonetheless, there is some evidence for the expression of the A 3 AR in the hippocampus, thalamus, and hypothalamus (Yaar et al., 2002) . Moreover, electrophysiological and biochemical evidence supports the localization of A 3 AR in the rat hippocampus (Dunwiddie et al., 1997; Macek et al., 1998) and cortex (Brand et al., 2001) , where they variously exert a direct neuroinhibitory action, or cause excitation by suppressing presynaptically located mGlu III autoreceptors (Macek et al., 1998) . Functional evidence also supports the presence of A 3 AR in the brain. The A 3 AR agonist N 6 -(3-iodobenzyl)adenosine-5 -N-methyluronamide (IB-MECA) depresses behavior (Jacobson et al., 1993) , and chronic treatment was found to be neuroprotective in the gerbil model of ischemia (von Lubitz et al., 1994) .
While the lack of high affinity A 3 AR specific radioligands and other pharmacological tools have impeded characterization of the localization and activity of the A 3 AR in general, the function of the A 3 AR in the cardiovascular system was substantially illuminated by the development of the A 3 AR null (A 3 AR −/− ) mouse. Similarly, A 3 AR −/− mice have the potential for providing the functional equivalent of A 3 antagonist administration by mitigating the question of A 3 AR ligand specificity. Therefore, we performed behavioral and provocative functional characterizations of A 3 AR −/− mice in order to elucidate the function of the A 3 receptor in the CNS.
MATERIALS AND METHODS
MRS 1523 (5-propyl-2-ethyl-4-propyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate) was purchased from Sigma-RBI (St. Louis, MO). This adenosine receptor antagonist was dissolved in 100% dimethylsulfoxide(DMSO) as a 5-mM stock solution. Injection vehicles were made by diluting the stock into Alkamuls-620, then phosphate buffered saline, pH 7.4, to yield a final composition of 5%/20%/75%. All other chemicals were from standard commercial sources and of analytical grade.
Animals
Two genotypes of mice were used: adenosine A 3 receptor knockout (A 3 AR −/− ) mice developed by Merck Research Laboratories, and wild-type (A 3 AR +/+ ) control mice. A description of the generation of an earlier strain of A 3 AR −/− mice by Merck Research Laboratories has been described (Salvatore et al., 2000) . These A 3 AR −/− mice were backcrossed against C57Bl/6 mice (Taconic Farms, Germantown, New York) for 12 generations to obtain a congenic line. Male mice (6-8 weeks of age, approximately 30 g) were used in all studies. The mice were housed in polypropylene cages with free access to food and water in an AALAC-certified vivarium. The vivarium was maintained on a 12-h light: 12-h dark cycle (lights on at 7:00) with a room temperature of 22 ± 1 • C and relative humidity level of 50 ± 5%. All studies were approved by the NIH Institutional Animal Care and Use Committee and were conducted in compliance with the Guide for the Care and Use of Laboratory Animals.
Behavioral Studies
All behavioral studies were performed between 9 A.M. and 5 P.M. in mice acclimated to the testing room.
Tests of Nociception
The sensitivity of mice to painful stimuli was assessed using the tail-flick and hotplate tests. In the tail-flick test, the tail of an unrestrained mouse was placed under the focused beam of a halogen projection lamp. The intensity of the lamp was adjusted so that the average latency before tail movement from the beam path by A 3 AR +/+ mice was approximately 5 s, with a cutoff latency of 10 s. The hot plate test involved the placement of mice onto a 55
• C plate (Columbus Instruments, Columbus, Ohio). The latency to the first incidence of hind-paw shaking or licking was recorded.
Spontaneous Locomotor Activity
Mice were placed into the center of an open field apparatus (40 × 40 cm; Columbus Instruments, Columbus, OH) under dim lighting. Motor activity parameters (distance traveled, number of vertical and stereotypic movements, ambulating and resting times) were monitored and recorded over a 30-min period. Monitoring was begun immediately after the mice were placed in the open field activity monitor.
Anxiety Tests
The apparatus used for the light-dark transition test consisted of a cage (25 × 40 × 20 cm) divided in two by a black partition with a small central opening connecting the chambers. One chamber had white walls and was brightly illuminated, whereas the other chamber was black and dimly illuminated. Mice were placed into the lit compartment and allowed to move freely between the two chambers for 5 min. The number of transitions between the two compartments, the time spent in each chamber, and the latency to the first transition were recorded. The elevated plusmaze consisted of two open (45 × 5 cm) and two enclosed arms of the same size, with 15 cm high walls. The arms were constructed of black acrylic radiating from a central platform (5 × 5 cm) to form a plus sign. The entire apparatus was elevated 30 cm above the floor. 
The Forced-Swim Test
Each mouse was placed individually into a Plexiglas cylinder (20 cm height × 10 cm diameter) filled with water (22
• C) to a height of 10 cm (Porsolt et al., 1979) . The total time the mouse spent immobile was recorded over a 6-min test period. Mice were judged immobile when they ceased swimming and remained floating motionless in the water, making only those movements necessary to keep their heads above the surface of the water.
The Tail-Suspension Test
This test is based on the observation that mice suspended by their tails show alternating periods of agitation and immobility (Steru et al., 1985) , and is predictive of antidepressant activity. Mice were suspended using adhesive tape placed 20 mm from the tip of the tail and were kept 20 cm from the nearest object. An observer blinded to the mouse genotype determined the cumulative duration of immobility over the 6-min duration of the test.
Contextual Fear Conditioning
Contextual, hippocampus-dependent memory was assessed in mice using the conditioned fear paradigm (Sterneck et al., 1998) . During the initial, contextconditioning phase, the animal learns to associate an aversive stimulus with the novel environment or the context in which it is placed. In this task, a novel environment (the distinct new context the animal is placed in) is paired with an electric shock administered on the training day. On the test day (24 h later), if the mouse has learned the context-shock association, then the same environmental context will elicit fear, resulting in a total lack of movement or freezing. The amount of time a mouse spends immobile or frozen on a given testing day is indicative of the degree of fear conditioning. Each mouse was placed in a test chamber (San Diego Instruments) and allowed to explore freely for 2 min. The conditioned stimulus (80 dB tone) was presented for 30 s followed by a mild (2 s, 0.5 mA) foot shock. Subsequently, the mouse was allowed to explore for 2 min. A second pairing of tone and shock was presented after this 2-min period, followed by another 1 min of exploration. The mouse was then removed from the chamber and returned to its home cage. The mouse was returned to the test chamber after 24 h for a 3-min period and the presence of freezing behavior recorded (context test). Contextual fear conditioning experiments were conducted on the seventh and eighth day after the second day of CO exposure.
Carbon Monoxide-Induced Neurodegeneration
Carbon monoxide exposure was carried out as previously described . Each mouse was placed in an acrylic cylinder (10 cm × 3 cm radius) with gas entry and exit barbs. The subject was exposed to pure CO gas until it began gasping (about 20 s after exposure at the rate of 45 mL/min), then was rapidly removed to room air. Animals were exposed for 2 days, five times a day, with 1 h between each exposure. Core body temperature was maintained at 38
• C by placing the mice on a heating blanket immediately after the first CO exposure and for up to 2 h after the last exposure to avoid CO hypothermia, with subsequent blunting of hypoxic neurodegeneration .
MRS 1523 (1 mg/kg, i.p.) was administered for 5 days, with the last 2 days of administration overlapping the first 2 days of CO exposure. Control mice received vehicle.
Histology
Following the behavioral studies, mice were euthanized by AALAC-approved methods, their brains removed and placed overnight in 20% sucrose containing 0.025% DMSO. The next morning, the brain regions were blocked, and the samples flash-frozen in isopentane at −20
• C. Serial 20 µm thick sections of the entire hippocampus were cut, and mounted, stained with 1% cresyl violet, destained, differentiated, and coverslipped. Morphometric analysis of CA1-3 pyramidal neurons was performed by manually counting neurons in every fifth section of cresyl violetstained hippocampus at 400× magnification (Kustova et al., 1999) . Area measures of the pyramidal neuron layer (CA1-3) of the entire hippocampus were made using digitally acquired images of hippocampal sections at 4× magnification, stacked and summed to yield the final volume measurements (Meta-Morph, Universal Imaging, Downingtown, PA).
Statistical Analysis
Data are expressed as mean ± standard error for the indicated n. Statistical analyses were performed using either a t test or one-way ANOVA followed by Bonferroni's Multiple Comparison Test (Prism, GraphPAD Software, San Diego, CA).
RESULTS

Gross physical examination of A 3 AR
−/− mice revealed an 8% greater body weight than age-matched A 3 AR +/+ mice (22.0 ± 0.4 g, n = 12 vs. 23.8 ± 0.4 g, n = 11; A 3 AR +/+ and A 3 AR −/− respectively, P < 0.01, t test), and a 1.6% lower core body temperature (37.3 ± 0.1
• C, n = 12 vs. 36.7 ± 0.1 • C, n = 11; A 3 AR +/+ and A 3 AR −/− respectively, P < 0.01, t test). Moreover, A 3 AR −/− mice demonstrated a decrease in the threshold of pain sensitivity as assessed in the hot-plate test, with a 40% increase in the latency of the hind-paw response (P < 0.05, t test, Fig. 1(A) ). However, the latency to movement in the tail-flick test was unchanged (2.3 ± 0.1 s vs. 2.2 ± 0.1 s).
Locomotor activity in a novel environment was measured in the open field. A 3 AR −/− mice showed a small but significant increase in the distance traveled in the open field ( Fig. 1(B) ). Interestingly, there was no significant difference between the genotypes in the number of vertical movements ( Fig. 1(C) ). Moreover, A 3 AR −/− and A 3 AR +/+ mice performed equally well in the rotarod test (115 ± 20 s vs. 103 ± 21 s, n = 11 both groups; A 3 AR +/+ and A 3 AR −/− respectively). Basal levels of anxiety were assessed in the elevated plus-maze test. Although there was a trend toward increased time spent in the open arms by A 3 AR −/− mice, this did not reach significance (Fig. 2(A) ). However, the number of open-and closed-arm entries made by A 3 AR −/− mice were significantly higher (113, 67%, respectively) than A 3 AR +/+ mice ( Fig. 2(B) and (C)). A 3 AR −/− and A 3 AR +/+ mice did not differ in the time spent in the lit compartment in the light-dark transition test (120 ± 10 s for A 3 AR +/+ , n = 12 and 140 ± 9 s for the A 3 AR −/− mice, n = 12). Nonetheless, A 3 AR −/− mice showed a significant, 95% increase in the number of transitions between the two compartments (18.7 ± 2.0, n = 12 vs. 33.2 ± 2.9, n = 12; A 3 AR +/+ and A 3 AR −/− mice, respectively, P < 0.01, t test). The behavior of the A 3 AR −/− and age-matched A 3 AR +/+ mice in the Porsolt forced swim test and tail suspension test was also investigated. In the tail suspension test, the A 3 AR −/− mice spent significantly more time immobile than A 3 AR +/+ mice, consistent with an increased level of "behavioral despair" (Fig. 3(A) ). Increased immobility (49%) was also observed in A 3 AR −/− mice in the forced swim test (Fig. 3(B) ).
Finally, the sensitivity of A 3 AR −/− mice to hypoxic neurodegeneration was investigated using an in vivo model of CO-induced delayed amnesia and neuronal damage (Maurice et al., 1994 (Maurice et al., , 1999 Nabeshima et al., 1991) . The influence of CO exposure on the locomotion of A 3 AR −/− mice was observed in the open field test. CO exposure decreased the locomotion of both genotypes of mice (Fig. 4(A) ), but the relative decrease was approximately 85% greater in A 3 AR −/− than A 3 AR +/+ mice (Fig. 4(B) ). CO-induced changes in cognition were also examined using a contextual fear-conditioning paradigm. Basal, pre-CO exposure rates of contextual learning were similar in mice of both genotypes (the ratio of the number of photobeam interruptions during the context test relative to the conditioning test was 19.6 ± 2.3% in A 3 AR +/+ mice, n = 14; and 19.1 ± 1.5% in A 3 AR −/− mice, n = 12). In contrast, A 3 AR −/− mice did not perform as well as A 3 AR +/+ mice after CO exposure (Fig. 5 ). During the conditioning phase, A 3 AR −/− mice showed almost the same number of photobeam interruptions as A 3 AR +/+ mice, consistent with equal freezing times ( Fig. 5(A) , conditioning). Strikingly, A 3 AR −/− mice interrupted the photobeams more frequently during context testing conducted 24 h after conditioning (Fig. 5(A) , test-context), with their freezing time in response to shock-associated context being lower than A 3 AR +/+ mice. This difference is clearer when performance is presented as the ratio of photobeam interruptions during context testing to the number of photobeam interruptions during the conditioning period × 100 (Fig. 5(B) ). When the retention test was conducted 1 month after conditioning, A 3 AR −/− mice showed a deficit in memory for the environmental context associated with an aversive stimulus. This was manifested as a 67% increase in the number of photobeam interruptions (200 ± 21 for A 3 AR +/+ , n = 8; 340 ± 18 for A 3 AR −/− , n = 9, P < 0.001, t test). Administration of the A 3 AR antagonist MRS 1523 to A 3 AR +/+ mice for 5 days (protocol 2) resulted in similar changes in contextual fear conditioning as the deletion of the A 3 AR (Fig. 5) , with the number of photobeam interruptions decreased during conditioning, but enhanced in context testing.
Finally, we examined whether the post-hypoxic cognitive deficits displayed by the A 3 AR −/− mice were associated with neuronal death in the CA1-3 subfields of the hippocampus. Histological studies showed that 7 days after exposure to CO, a moderate loss of pyramidal neurons was observed in all subfields of the hippocampus. Closer examination of the CA2 and CA3 regions of the hippocampus revealed that neuronal density in the CO-exposed mice was significantly more pronounced in the A 3 AR −/− mice than A 3 AR +/+ (Figs. 6 and 7) ( p < 0.05, one-way ANOVA). Consistent with the enhanced loss of pyramidal neurons in A 3 AR −/− mice, A 3 AR +/+ , mice administered the A 3 AR antagonist MRS 1523 showed a decrease in neuronal density in CA2-3 pyramidal neuron subfields.
DISCUSSION
The modulatory role of A 1 and A 2A ARs in the CNS is well established, and behavioral consequences of the deletion of these receptor subtypes have been described Fig. 6 . Effect of CO treatment on hippocampal pyramidal neurons in the CA2-3 subfields. Treatment groups included naïve wild type and A 3 AR −/− mice, and CO-exposed animals (wild type, A 3 AR −/− and wild type mice after vehicle administration and after A 3 R antagonist MRS 1523 administration). There was no difference in neuron density between naïve wild type and A 3 AR −/− mice. However, after CO treatment, all groups showed a lower neuron density than untreated mice, neuronal death after CO exposure being more pronounced in A 3 AR −/− mice than in wild type mice. * Significantly different from respective naïve groups, P < 0.05; a Significantly different from CO-treated A 3 AR +/+ mice, P < 0.05; * * Significantly different from A 3 AR +/+ mice, ANOVA and Tukey's test. Each bar represents the mean ± SEM of data from 6 to 12 mice. (Gimenez-Llort et al., 2002) . In contrast, the A 3 AR have been implicated in a variety of peripheral organ system functions, including regulating cellular components of the immune system (Ramkumar et al., 1993; Sajjadi et al., 1996; Salvatore et al., 2000; Shepherd et al., 1996) , cardiovascular function (Cerniway et al., 2001; Guo et al., 2001; Lasley et al., 1999; van Schaick et al., 1996; Zhao et al., 2000) , and apoptosis (Appel et al., 2001; Di Iorio et al., 2002) . However, understanding of their function(s) in the CNS has been impeded, both by a lack of specific ligands and the low density of receptors (Rivkees et al., 2000) . In an attempt to understand the role of the A 3 AR in CNS function, we have utilized mice with a deletion of the A 3 AR receptor (A 3 AR −/− mice) in a battery of behavioral tests. Moreover, given evidence of a cardioprotective action of the A 3 AR (Parsons et al., 2000) , we investigated the potential influence of these receptors on neuronal survival following a hypoxic insult.
Our initial characterization of the behavioral effects of the functional deletion of the A 3 AR in mice showed that A 3 AR −/− mice manifested a decreased sensitivity to some painful stimuli, as evidenced by the increase in latency in the hot plate, but not tail-flick test. This observation reflects a decrease in the supraspinal processing and "recognition" of painful stimuli, and may be consistent with preliminary observations of the localization of A 3 AR in thalamic nuclei, but not in the spinal cord (Yaar et al., 2002) , where they may play a role in processing nociceptive information. Interestingly, significant increases in some aspects of motor function were also observed in A 3 AR −/− mice. Evidence for a slight increase in locomotor activity was observed in three different tests: activity in the open field; number of arm entries in the elevated plus maze; and number of transitions in the light/dark box. This change in motor activity appears to be selective, as there was no increase in the number of vertical movements, or evidence of "ataxia," as defined using the rotarod, and argues against a nonselective increase in motor activity resulting from the process of generating transgenic mice. While the brain region(s) involved in this hyperlocomotion remains unknown, the disinhibition of cortical neurons resulting from the deletion of the A 3 AR (Brand et al., 2001 ) may play a role, and is consistent with the substantial depression of motor activity observed after administration of the A 3 AR agonist IB-MECA (Jacobson et al., 1993) .
In addition to the evidence for a potential role of the A 3 AR in motor function and nociception, A 3 AR may regulate other behavioral activities. Initial interpretation of the performance of the A 3 AR −/− mice in the elevated plus maze and light/dark box suggests a reduction in their level of anxiety or fearfulness, as evidenced by the increase in exploratory activity. Closer examination suggests that these results may reflect the increased motor activity of these mice, as there was no significant increase in the amount of time spent in the open arms of the plus maze, or in the illuminated side of the light/dark box. While AR antagonists have been proposed as antidepressants (El Yacoubi et al., 2001) , A 3 AR −/− mice showed an increase in the amount of time spent immobile in two tests of behavioral depression. This response is not adequately explained by a decrease in motor activity, particularly in view of the increased locomotion expressed by this genotype. A 3 AR have been found to modulate hippocampal serotonin levels, possibly by regulating release and/or reuptake (Okada et al., 1999) . Deletion of these receptors may reduce the levels of free serotonin or catecholamines, thereby acting as a behavioral depressant and increasing immobility time in the forced-swim and tail-hang tests, which are predictive of antidepressant actions (Porsolt et al., 1979; Steru et al., 1985) . In contrast with the above studies, a role for the A 3 AR in aspects of neuroprotection was supported by studies with the A 3 AR −/− mice. While the A 1 and A 2A ARs are associated with the protective functions of adenosine, decreasing energy demand while increasing energy supply (Jacobson, 1998) , respectively, the role of the A 3 AR has been more difficult to generalize, as both protective and damaging effects have been noted (Appel et al., 2001; Cerniway et al., 2001; Fishman et al., 2002) . Repetitive exposure of mice to CO gas induces a long-lasting but delayed amnesia measured 1 week after exposure (Nabeshima et al., 2001) , accompanied by dose-dependent death of hippocampal pyramidal neurons . This relatively mild insult was used to quantify changes in neuronal vulnerability to hypoxia that may occur in the absence of the A 3 AR. Therefore, we characterized the behavior of a strain of A 3 AR −/− mice in a wide range of behavioral tests with or without mild ischemic damage induced by CO exposure. In the case of repeated brief exposure to CO, we found that mice lacking the A 3 AR are more vulnerable than control animals to hippocampal damage following hypoxia. By histological examination 1 week after the exposure to CO, a moderate neuronal loss in all regions of the hippocampus was observed in all mice, but the degree of neuronal death in the CA2-3 subfields was more pronounced in A 3 AR −/− mice than in wild type. The hypoxic damage also impacted cognition, with CO-induced hypoxia causing a decline in cognitive function in a test of contextual fear conditioning that was more pronounced in A 3 AR −/− mice. While this increase in test-context motor activity may reflect the increase in general locomotor activity expressed by A 3 AR −/− mice in select environments such as the open field, plus-maze and light-dark box, there was apparently no difference between the genotypes in performance in the contextual fear conditioning test before CO exposure. Moreover, CO exposure appeared to reduce the motor activity of the A 3 AR −/− mice to the level of the wild-type mice. An additional factor which may explain the apparent decrease in cognitive function manifested by CO exposed A 3 AR −/− mice is the increased threshold for nociception indicated by the hot-plate test. This would effectively reduce the intensity of the aversive stimulus which the environmental context is associated with, potentially slowing the rate and efficiency of learning in these mice. Nonetheless, even the evidence for changes in nociception in the A 3 AR −/− mice is unclear, as it reflects performance in the hot plate, but not tail-flick test.
While pre-CO exposure control testing in the contextual fear conditioning assay was performed to help mitigate the influence of potentially confounding factors, additional cognitive testing using paradigms that either do not require a nociceptive input, or extensive locomotor activity (e.g., operant conditioning) may be required before any conclusions regarding the A 3 AR, learning and memory in both intact and lesioned mice can be reached. This task may be eased by the observation that the apparent neuronal vulnerability observed in the A 3 AR −/− mice was duplicated by blockade of the receptor. Repeated administration of the A 3 AR-selective antagonist MRS 1523, which is selective for A 3 AR in both primates and rodents, resulted in a greater degree of neuronal damage and impairment of contextual memory than after vehicle administration. The role of the A 3 AR in neuroprotection and cognition may be more extensively tested in the future by chronic administration of MRS 1523 in concert with various hypoxia/ischemia lesioning paradigms, and/or with specific tests of cognition. Thus, in acute global brain ischemia it appears that either pharmacological blockade or genetic deletion of the A 3 AR in the mouse is detrimental. Although the damage incurred by the CO treatment was milder than in other models of global ischemia, such as bilateral occlusion of the carotid arteries in gerbils (von Lubitz et al., 1994) , differences based on the presence or absence of the A 3 AR were evident. This implies that the levels of adenosine in the brain during hypoxia/ischemia are sufficient to activate the A 3 AR.
In summary, the A 3 AR −/− mouse reveals a number of CNS functions where the A 3 AR plays a role, including nociception, locomotion, behavioral depression, and neuroprotection. The finding that deletion of the A 3 AR has a detrimental effect in a model of mild hypoxia suggests the possible use of A 3 AR agonists in the treatment of ischemic, degenerative conditions of the CNS. A 3 AR agonists are already under development for other clinical indications, such as antineoplastics (Fishman et al., 2002) . As the development of these pharmacotherapeutic agents progresses , the utility of pharmacologically regulating CNS activities via the A 3 AR may become more apparent.
